The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
Open accessAbstract
BACKGROUND: Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies. PATIENTS AND METHODS: Patients with active or historical cancer and a laboratory-confirmed SARS-CoV-2 diagnosis recorded between 17 March and 18 November 2020 were included. The primary outcome was COVID-19 severity measured on an ordinal scale (uncomplicated, hospitalized, admitted to intensive care unit, mechanically ventilated, died within 30 days). Multivariable regression models included demographics, cancer status, anticancer therapy and timing, COVID-19-directed therapies, and laboratory measurements (among hospitalized patients). RESULTS: A total of 4966 patients were included (median age 66 years, 51% female, 50% non-Hispanic white); 2872 (58%) were hospitalized and 695 (14%) died; 61% had cancer that was present, diagnosed, or treated within the year prior to COVID-19 diagnosis. Older age, male sex, obesity, cardiovascular and pulmonary comorbidities, renal disease, diabetes mellitus, non-Hispanic black race, Hispanic ethnicity, worse Eastern Cooperative Oncology Group performance status, recent cytotoxic chemotherapy, and hematologic malignancy were associated with higher COVID-19 severity. Among hospitalized patients, low or high absolute lymphocyte count; high absolute neutrophil count; low platelet count; abnormal creatinine; troponin; lactate dehydrogenase; and C-reactive protein were associated with higher COVID-19 severity. Patients diagnosed early in the COVID-19 pandemic (January-April 2020) had worse outcomes than those diagnosed later. Specific anticancer therapies (e.g. R-CHOP, platinum combined with etoposide, and DNA methyltransferase inhibitors) were associated with high 30-day all-cause mortality. CONCLUSIONS: Clinical factors (e.g. older age, hematological malignancy, recent chemotherapy) and laboratory measurements were associated with poor outcomes among patients with cancer and COVID-19. Although further studies are needed, caution may be required in utilizing particular anticancer therapies. CLINICAL TRIAL IDENTIFIER: NCT04354701.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
The REDCap consortium: building an international community of software platform partners
Harris, P. A., Taylor, R., Minor, B. L., Elliott, V., Fernandez, M., O'Neal, L., McLeod, L., Delacqua, G., Delacqua, F., Kirby, J., et al. (2019) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2019.103208 · Cited by 24,013
Multiple imputation using chained equations: Issues and guidance for practice
White, I. R., Royston, P., & Wood, A. M. (2011) · Statistics in Medicine · doi:10.1002/sim.4067 · Cited by 9,792
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Factors associated with COVID-19-related death using OpenSAFELY
Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2521-4 · Cited by 6,674
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., Li, C., Ai, Q., Lu, W., Liang, H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30096-6 · Cited by 4,384 · cited 6×
“25) 75 (66-83) Sex Female 1193 (58) 832 (50) 109 (47) 111 (38) 282 (41) Male 879 (42) 841 (50) 123 (53) 180 (62) 413 (59) Missing/unknown 0 (0) 2 (<1) 0 (0) 1 (<1) 0 (0) Race and ethnicity Non-Hispanic white 1100 (53) 802 (48) 116 (50) 125 (43) 342 (49) Non-Hispanic black 369 (18) 389 (23) 51 (22) 76 (26) 183 (26) His…”
InfluentialWHO Coronavirus Disease (COVID-19) Dashboard
(2020) · Bangladesh Physiotherapy Journal · doi:10.46945/bpj.10.1.03.01 · Cited by 3,806
UpSetR: an R package for the visualization of intersecting sets and their properties
Conway, J. R., Lex, A., & Gehlenborg, N. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx364 · Cited by 3,586
Wynants, L., Van Calster, B., Bonten, M. M., Collins, G. S., Debray, T. P., De Vos, M., Haller, M. C., Heinze, G., Moons, K. G., Riley, R. D., et al. (2020) · doi:10.1101/2020.03.24.20041020 · Cited by 3,070
UpSet: Visualization of Intersecting Sets
Lex, A., Gehlenborg, N., Strobelt, H., Vuillemot, R., & Pfister, H. (2014) · IEEE Transactions on Visualization and Computer Graphics · doi:10.1109/tvcg.2014.2346248 · Cited by 2,323
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31187-9 · Cited by 1,726
Self-citationEstimation of the probability of an event as a function of several independent variables
WALKER, S. H., & DUNCAN, D. B. (1967) · Biometrika · doi:10.1093/biomet/54.1-2.167 · Cited by 1,682
A minimal common outcome measure set for COVID-19 clinical research
Marshall, J. C., Murthy, S., Diaz, J., Adhikari, N. K., Angus, D. C., Arabi, Y. M., Baillie, K., Bauer, M., Berry, S., Blackwood, B., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30483-7 · Cited by 1,641
Dai, M., Liu, D., Liu, M., Zhou, F., Li, G., Chen, Z., Zhang, Z., You, H., Wu, M., Zheng, Q., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0422 · Cited by 1,589
Haslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413 · cited 3×
“Never treated 159 (8) 144 (9) 21 (9) 26 (9) 63 (9) 0-4 weeks 697 (34) 530 (32) 66 (28) 96 (33) 220 (32) 1-3 months 139 (7) 130 (8) 14 (6) 15 (5) 77 (11) >3 months 1012 (49) 793 (47) 113 (49) 137 (47) 289 (42) Missing/unknown 65 (3) 78 (5) 18 (8) 18 (6) 46 (7) Modality of active anticancer therapy None 1171 (57) 953 (5…”
Gandhi, R. T., Lynch, J. B., & del Rio, C. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp2009249 · Cited by 1,307
Lee, L. Y., Cazier, J.-B., Angelis, V., Arnold, R., Bisht, V., Campton, N. A., Chackathayil, J., Cheng, V. W., Curley, H. M., Fittall, M. W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31173-9 · Cited by 1,103 · cited 5×
“25) 75 (66-83) Sex Female 1193 (58) 832 (50) 109 (47) 111 (38) 282 (41) Male 879 (42) 841 (50) 123 (53) 180 (62) 413 (59) Missing/unknown 0 (0) 2 (<1) 0 (0) 1 (<1) 0 (0) Race and ethnicity Non-Hispanic white 1100 (53) 802 (48) 116 (50) 125 (43) 342 (49) Non-Hispanic black 369 (18) 389 (23) 51 (22) 76 (26) 183 (26) His…”
BackgroundInfluentialMackey, K., Ayers, C. K., Kondo, K. K., Saha, S., Advani, S. M., Young, S., Spencer, H., Rusek, M., Anderson, J., Veazie, S., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-6306 · Cited by 1,076
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
Yu, J., Ouyang, W., Chua, M. L. K., & Xie, C. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0980 · Cited by 1,071
Regression Models in Clinical Studies: Determining Relationships Between Predictors and Response
Harre, F. E., Lee, K. L., & Pollock, B. G. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.15.1198 · Cited by 957
Izcovich, A., Ragusa, M. A., Tortosa, F., Lavena Marzio, M. A., Agnoletti, C., Bengolea, A., Ceirano, A., Espinosa, F., Saavedra, E., Sanguine, V., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0241955 · Cited by 660
Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis
Lippi, G., & Plebani, M. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.004 · Cited by 652
Determinants of COVID-19 disease severity in patients with cancer
Robilotti, E. V., Babady, N. E., Mead, P. A., Rolling, T., Perez-Johnston, R., Bernardes, M., Bogler, Y., Caldararo, M., Figueroa, C. J., Glickman, M. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0979-0 · Cited by 628
Self-citationGarassino, M. C., Whisenant, J. G., Huang, L.-C., Trama, A., Torri, V., Agustoni, F., Baena, J., Banna, G., Berardi, R., Bettini, A. C., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30314-4 · Cited by 612
Self-citationTian, J., Yuan, X., Xiao, J., Zhong, Q., Yang, C., Liu, B., Cai, Y., Lu, Z., Wang, J., Wang, Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30309-0 · Cited by 528
Montopoli, M., Zumerle, S., Vettor, R., Rugge, M., Zorzi, M., Catapano, C. V., Carbone, G. M., Cavalli, A., Pagano, F., Ragazzi, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.479 · Cited by 518
Lai, A. G., Pasea, L., Banerjee, A., Hall, G., Denaxas, S., Chang, W. H., Katsoulis, M., Williams, B., Pillay, D., Noursadeghi, M., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-043828 · Cited by 447
Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic
Hanna, T. P., Evans, G. A., & Booth, C. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0362-6 · Cited by 400
Wang, Q., Berger, N. A., & Xu, R. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6178 · Cited by 390
Ferritin in the coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
Cheng, L., Li, H., Li, L., Liu, C., Yan, S., Chen, H., & Li, Y. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23618 · Cited by 387
COVID-19 and Cancer: Current Challenges and Perspectives
Bakouny, Z., Hawley, J. E., Choueiri, T. K., Peters, S., Rini, B. I., Warner, J. L., & Painter, C. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.018 · Cited by 275
Self-citationChemotherapy and COVID-19 Outcomes in Patients With Cancer
Jee, J., Foote, M. B., Lumish, M., Stonestrom, A. J., Wills, B., Narendra, V., Avutu, V., Murciano-Goroff, Y. R., Chan, J. E., Derkach, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01307 · Cited by 260
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers
Luo, J., Rizvi, H., Egger, J. V., Preeshagul, I. R., Wolchok, J. D., & Hellmann, M. D. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0596 · Cited by 232
Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data
Giannakoulis, V. G., Papoutsi, E., & Siempos, I. I. (2020) · JCO Global Oncology · doi:10.1200/go.20.00225 · Cited by 226
Chari, A., Samur, M. K., Martinez-Lopez, J., Cook, G., Biran, N., Yong, K., Hungria, V., Engelhardt, M., Gay, F., García Feria, A., et al. (2020) · Blood · doi:10.1182/blood.2020008150 · Cited by 187
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
Pinato, D. J., Zambelli, A., Aguilar-Company, J., Bower, M., Sng, C. C. T., Salazar, R., Bertuzzi, A., Brunet, J., Mesia, R., Seguí, E., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0773 · Cited by 179
Roles of CD38 in the Immune Response to Infection
Glaría, E., & Valledor, A. F. (2020) · Cells · doi:10.3390/cells9010228 · Cited by 149
Rivera, D. R. R., Peters, S., Panagiotou, O. A., Shah, D. P., Kuderer, N. M., Hsu, C., Rubinstein, S. M., Lee, B. J., Choueiri, T. K., Lopes, G. D. L., Jr., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0941 · Cited by 137
Self-citationCOVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study
Brar, G. S., Pinheiro, L. C., Shusterman, M., Swed, B., Reshetnyak, E., Soroka, O., Chen, F., Yamshon, S., Vaughn, J. L., Martin, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01580 · Cited by 136
Self-citationAlbiges, L. K., Foulon, S., Bayle, A., Gachot, B., Pommeret, F., Willekens, C., Stoclin, A., Merad-Boudia, M., Griscelli, F., Lacroix, L., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00120-5 · Cited by 116
Hultcrantz, M. L., Richter, J. R., Rosenbaum, C. A., Patel, D., Smith, E. L., Korde, N., Lu, S. X., Mailankody, S., Shah, U. A., Lesokhin, A. M., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0102 · Cited by 93
Pennell, N. A., Dillmon, M. S., Levit, L. A., Moushey, E. A., Alva, A. S., Blau, S. H., Cannon, T. L., Dickson, N. R., Diehn, M., Gönen, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02953 · Cited by 89
Self-citationCrowdsourcing a crisis response for COVID-19 in oncology
Desai, A. P., Warner, J. L., Kuderer, N. M., Thompson, M., Painter, C., Lyman, G. H., & Lopes, G. D. L., Jr. (2020) · Nature Cancer · doi:10.1038/s43018-020-0065-z · Cited by 80
Self-citationAbidi, M. Z., Aboulafia, D. M., Accordino, M. K., Acoba, J. D., Ahluwalia, M. S., Ahmad, S. A., Ajmera, A., Alimohamed, S. I., Altman, J. K., Angevine, A. H., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.022 · Cited by 31
Self-citationApplying Lessons Learned From Low-Resource Settings to Prioritize Cancer Care in a Pandemic
DeBoer, R. J., Fadelu, T. A., Shulman, L. N., & Loon, K. V. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2976 · Cited by 23
Desai, A. P., Khaki, A. R., & Kuderer, N. M. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.5461 · Cited by 8
Self-citationGarrett-Mayer, E. S., & Rini, B. I. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4886 · Cited by 7
Self-citation
Cited by
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
Bange, E. M., Han, N. A., Wileyto, P., Kim, J. Y., Gouma, S., Robinson, J., Greenplate, A. R., Hwee, M. A., Porterfield, F., Owoyemi, O., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01386-7 · Cited by 519
Self-citationSeroconversion rates following COVID-19 vaccination among patients with cancer
Thakkar, A., Gonzalez-Lugo, J. D., Goradia, N., Gali, R., Shapiro, L. C., Pradhan, K., Rahman, S., Kim, S. Y., Ko, B., Sica, R. A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.002 · Cited by 344
Self-citationPritchett, J. C., Borah, B. J., Desai, A. P., Xie, Z., Saliba, A. N., Leventakos, K., Coffey, J. D., Pearson, K. K., Speicher, L. L., Orenstein, R., et al. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00307 · Cited by 32
Self-citation
Metadata
- Authors
- Grivas, P., Khaki, A. R., Wise-Draper, T. M., French, B., Hennessy, C., Hsu, C.-Y., Shyr, Y., Li, X., Choueiri, T. K., Painter, C. A., Peters, S., Rini, B. I., Thompson, M. A., Mishra, S., Rivera, D. R., Acoba, J. D., Abidi, M. Z., Bakouny, Z., Bashir, B., Bekaii-Saab, T., Berg, S., Bernicker, E. H., Bilen, M. A., Bindal, P., Bishnoi, R., Bouganim, N., Bowles, D. W., Cabal, A., Caimi, P. F., Chism, D. D., Crowell, J., Curran, C., Desai, A., Dixon, B., Doroshow, D. B., Durbin, E. B., Elkrief, A., Farmakiotis, D., Fazio, A., Fecher, L. A., Flora, D. B., Friese, C. R., Fu, J., Gadgeel, S. M., Galsky, M. D., Gill, D. M., Glover, M. J., Goyal, S., Grover, P., Gulati, S., Gupta, S., Halabi, S., Halfdanarson, T. R., Halmos, B., Hausrath, D. J., Hawley, J. E., Hsu, E., Huynh-Le, M., Hwang, C., Jani, C., Jayaraj, A., Johnson, D. B., Kasi, A., Khan, H., Koshkin, V. S., Kuderer, N. M., Kwon, D. H., Lammers, P. E., Li, A., Loaiza-Bonilla, A., Low, C. A., Lustberg, M. B., Lyman, G. H., McKay, R. R., McNair, C., Menon, H., Mesa, R. A., Mico, V., Mundt, D., Nagaraj, G., Nakasone, E. S., Nakayama, J., Nizam, A., Nock, N. L., Park, C., Patel, J. M., Patel, K. G., Peddi, P., Pennell, N. A., Piper-Vallillo, A. J., Puc, M., Ravindranathan, D., Reeves, M. E., Reuben, D. Y., Rosenstein, L., Rosovsky, R. P., Rubinstein, S. M., Salazar, M., Schmidt, A. L., Schwartz, G. K., Shah, M. R., Shah, S. A., Shah, C., Shaya, J. A., Singh, S. R. K., Smits, M., Stockerl-Goldstein, K. E., Stover, D. G., Streckfuss, M., Subbiah, S., Tachiki, L., Tadesse, E., Thakkar, A., Tucker, M. D., Verma, A. K., Vinh, D. C., Weiss, M., Wu, J. T., Wulff-Burchfield, E., Xie, Z., Yu, P. P., Zhang, T., Zhou, A. Y., Zhu, H., Zubiri, L., Shah, D. P., Warner, J. L., & Lopes, G.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 32
- Issue
- 6
- Pages
- 787-800
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3136076419
- Cited by
- 309
- References
- 48
- FWCI
- 22.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.